Trade Cross Country - CCRN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.14 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Cross Country Healthcare Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 18.38 |
Open* | 18.45 |
1-Year Change* | -22.71% |
Day's Range* | 18.09 - 18.64 |
52 wk Range | 15.65-31.82 |
Average Volume (10 days) | 267.61K |
Average Volume (3 months) | 8.03M |
Market Cap | 761.02M |
P/E Ratio | 7.67 |
Shares Outstanding | 35.15M |
Revenue | 2.23B |
EPS | 2.82 |
Dividend (Yield %) | N/A |
Beta | 0.78 |
Next Earnings Date | Feb 20, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 28, 2024 | 18.64 | 0.19 | 1.03% | 18.45 | 18.67 | 18.08 |
Mar 27, 2024 | 18.38 | -0.03 | -0.16% | 18.41 | 18.57 | 18.11 |
Mar 26, 2024 | 18.36 | 0.38 | 2.11% | 17.98 | 18.43 | 17.98 |
Mar 25, 2024 | 18.24 | -0.19 | -1.03% | 18.43 | 18.52 | 17.95 |
Mar 22, 2024 | 18.37 | -0.39 | -2.08% | 18.76 | 18.94 | 18.19 |
Mar 21, 2024 | 18.71 | -0.15 | -0.80% | 18.86 | 18.86 | 18.39 |
Mar 20, 2024 | 18.83 | 0.37 | 2.00% | 18.46 | 19.08 | 18.07 |
Mar 19, 2024 | 19.00 | 1.30 | 7.34% | 17.70 | 19.18 | 17.70 |
Mar 18, 2024 | 17.85 | 1.05 | 6.25% | 16.80 | 17.89 | 16.78 |
Mar 15, 2024 | 17.04 | 0.59 | 3.59% | 16.45 | 17.11 | 16.45 |
Mar 14, 2024 | 16.81 | -0.68 | -3.89% | 17.49 | 17.49 | 16.79 |
Mar 13, 2024 | 17.47 | -0.50 | -2.78% | 17.97 | 18.29 | 17.26 |
Mar 12, 2024 | 18.33 | 0.08 | 0.44% | 18.25 | 18.63 | 18.24 |
Mar 11, 2024 | 18.59 | 0.06 | 0.32% | 18.53 | 18.92 | 18.24 |
Mar 8, 2024 | 18.86 | 0.24 | 1.29% | 18.62 | 19.05 | 18.57 |
Mar 7, 2024 | 18.59 | 0.44 | 2.42% | 18.15 | 18.80 | 17.92 |
Mar 6, 2024 | 18.11 | 0.34 | 1.91% | 17.77 | 18.12 | 17.34 |
Mar 5, 2024 | 17.72 | -0.35 | -1.94% | 18.07 | 18.44 | 17.71 |
Mar 4, 2024 | 18.55 | 0.05 | 0.27% | 18.50 | 18.94 | 17.92 |
Mar 1, 2024 | 18.42 | 0.21 | 1.15% | 18.21 | 18.44 | 17.80 |
Cross Country Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, May 1, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q1 2024 Cross Country Healthcare Inc Earnings Release Q1 2024 Cross Country Healthcare Inc Earnings ReleaseForecast -Previous - |
Wednesday, May 15, 2024 | ||
Time (UTC) 16:00 | Country US
| Event Cross Country Healthcare Inc Annual Shareholders Meeting Cross Country Healthcare Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 2806.61 | 1676.65 | 836.417 | 822.224 | 816.484 |
Revenue | 2806.61 | 1676.65 | 836.417 | 822.224 | 816.484 |
Cost of Revenue, Total | 2178.92 | 1301.65 | 633.685 | 618.215 | 606.921 |
Gross Profit | 627.686 | 374.999 | 202.732 | 204.009 | 209.563 |
Total Operating Expense | 2537.23 | 1537.35 | 845.577 | 839.913 | 829.443 |
Selling/General/Admin. Expenses, Total | 333.818 | 220.075 | 176.844 | 183.967 | 182.434 |
Depreciation / Amortization | 12.576 | 9.852 | 12.671 | 14.075 | 11.78 |
Unusual Expense (Income) | 11.912 | 5.768 | 22.377 | 23.656 | 28.308 |
Operating Income | 269.38 | 139.304 | -9.16 | -17.689 | -12.959 |
Interest Income (Expense), Net Non-Operating | -14.391 | -6.866 | -2.89 | -6.59 | -5.654 |
Other, Net | 1.336 | 0.77 | -0.28 | 0.068 | 0.418 |
Net Income Before Taxes | 256.325 | 133.208 | -12.33 | -24.211 | -18.195 |
Net Income After Taxes | 188.461 | 132.002 | -12.142 | -55.943 | -15.617 |
Minority Interest | 0 | 0 | -0.82 | -1.77 | -1.234 |
Net Income Before Extra. Items | 188.461 | 132.002 | -12.962 | -57.713 | -16.851 |
Net Income | 188.461 | 132.002 | -12.962 | -57.713 | -16.951 |
Income Available to Common Excl. Extra. Items | 188.461 | 132.002 | -12.962 | -57.713 | -16.851 |
Income Available to Common Incl. Extra. Items | 188.461 | 132.002 | -12.962 | -57.713 | -16.951 |
Diluted Net Income | 188.461 | 132.002 | -12.962 | -57.713 | -16.951 |
Diluted Weighted Average Shares | 37.536 | 37.392 | 36.088 | 35.815 | 35.657 |
Diluted EPS Excluding Extraordinary Items | 5.02081 | 3.53022 | -0.35918 | -1.61142 | -0.47259 |
Diluted Normalized EPS | 5.25413 | 3.68308 | 0.04387 | -1.18209 | 0.04345 |
Total Extraordinary Items | -0.1 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 540.695 | 622.707 | 628.218 | 636.098 | 753.561 |
Revenue | 540.695 | 622.707 | 628.218 | 636.098 | 753.561 |
Cost of Revenue, Total | 417.556 | 483.284 | 489.276 | 492.553 | 583.156 |
Gross Profit | 123.139 | 139.423 | 138.942 | 143.545 | 170.405 |
Total Operating Expense | 507.229 | 578.91 | 578.57 | 583.923 | 676.636 |
Selling/General/Admin. Expenses, Total | 82.008 | 89.186 | 84.118 | 81.317 | 89.201 |
Depreciation / Amortization | 4.432 | 4.904 | 3.162 | 3.214 | 3.481 |
Unusual Expense (Income) | 3.233 | 1.536 | 2.014 | 6.839 | 0.798 |
Operating Income | 33.466 | 43.797 | 49.648 | 52.175 | 76.925 |
Interest Income (Expense), Net Non-Operating | -3.149 | -3.69 | -3.515 | -3.498 | -3.857 |
Other, Net | -0.011 | 0.012 | 0.217 | 0.027 | 1.084 |
Net Income Before Taxes | 30.306 | 40.119 | 46.35 | 48.704 | 74.152 |
Net Income After Taxes | 21.345 | 29.436 | 38.791 | 34.793 | 52.894 |
Minority Interest | 0 | ||||
Net Income Before Extra. Items | 21.345 | 29.436 | 38.791 | 34.793 | 52.894 |
Net Income | 21.345 | 29.436 | 38.791 | 34.793 | 52.894 |
Income Available to Common Excl. Extra. Items | 21.345 | 29.436 | 38.791 | 34.793 | 52.894 |
Income Available to Common Incl. Extra. Items | 21.345 | 29.436 | 38.791 | 34.793 | 52.894 |
Diluted Net Income | 21.345 | 29.436 | 38.791 | 34.793 | 52.894 |
Diluted Weighted Average Shares | 35.524 | 36.56 | 36.921 | 37.492 | 37.757 |
Diluted EPS Excluding Extraordinary Items | 0.60086 | 0.80514 | 1.05065 | 0.92801 | 1.40091 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.66496 | 0.83597 | 1.0963 | 1.05832 | 1.41598 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 675.673 | 508.273 | 183.111 | 183.357 | 194.905 |
Cash and Short Term Investments | 3.604 | 1.036 | 1.6 | 1.032 | 16.019 |
Cash & Equivalents | 3.604 | 1.036 | 1.6 | 1.032 | 16.019 |
Total Receivables, Net | 659.96 | 498.951 | 174.701 | 174.539 | 170.314 |
Accounts Receivable - Trade, Net | 641.611 | 493.91 | 170.003 | 169.528 | 166.128 |
Prepaid Expenses | 11.067 | 7.648 | 5.455 | 6.097 | 6.208 |
Other Current Assets, Total | 1.042 | 0.638 | 1.355 | 1.689 | 2.364 |
Total Assets | 947.839 | 732.809 | 356.973 | 382.374 | 427.003 |
Property/Plant/Equipment, Total - Net | 22.927 | 23.378 | 22.9 | 28.796 | 13.628 |
Property/Plant/Equipment, Total - Gross | 40.609 | 41.107 | 39.913 | 52.072 | 47.104 |
Accumulated Depreciation, Total | -17.682 | -17.729 | -17.013 | -23.276 | -33.476 |
Goodwill, Net | 163.268 | 119.49 | 90.924 | 101.066 | 101.06 |
Intangibles, Net | 44.723 | 48.244 | 40.731 | 50.857 | 75.584 |
Note Receivable - Long Term | 23.058 | 13.998 | 13.115 | 14.273 | 15.726 |
Other Long Term Assets, Total | 18.19 | 19.426 | 6.192 | 4.025 | 26.1 |
Total Current Liabilities | 271.64 | 199.77 | 93.423 | 85.465 | 85.386 |
Payable/Accrued | 109.753 | 49.877 | 45.726 | 43.744 | |
Accrued Expenses | 100.368 | 67.222 | 37.55 | 33.525 | 30.546 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 4.176 | 0 | 5.235 | |
Other Current Liabilities, Total | 12.822 | 18.619 | 5.996 | 6.214 | 5.861 |
Total Liabilities | 490.62 | 435.281 | 202.598 | 219.742 | 209.475 |
Total Long Term Debt | 148.735 | 176.366 | 53.408 | 70.974 | 77.944 |
Long Term Debt | 148.735 | 176.366 | 53.408 | 70.974 | 77.944 |
Deferred Income Tax | 0.247 | 0.19 | 6.592 | 7.523 | 0.095 |
Minority Interest | 0 | 0.534 | 0.868 | 0.67 | |
Other Liabilities, Total | 69.998 | 58.955 | 48.641 | 54.912 | 45.38 |
Total Equity | 457.219 | 297.528 | 154.375 | 162.632 | 217.528 |
Common Stock | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
Additional Paid-In Capital | 292.876 | 321.552 | 310.388 | 305.643 | 303.048 |
Retained Earnings (Accumulated Deficit) | 165.726 | -22.735 | -154.737 | -141.775 | -84.062 |
Other Equity, Total | -1.387 | -1.293 | -1.28 | -1.24 | -1.462 |
Total Liabilities & Shareholders’ Equity | 947.839 | 732.809 | 356.973 | 382.374 | 427.003 |
Total Common Shares Outstanding | 36.3026 | 37.0236 | 36.1773 | 35.8706 | 35.6257 |
Accounts Payable | 158.45 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 445.229 | 505.634 | 648.612 | 675.673 | 660.017 |
Cash and Short Term Investments | 14.301 | 0.673 | 0.291 | 3.604 | 30.32 |
Cash & Equivalents | 14.301 | 0.673 | 0.291 | 3.604 | 30.32 |
Total Receivables, Net | 423.419 | 496.841 | 636.125 | 659.96 | 617.099 |
Accounts Receivable - Trade, Net | 410.373 | 484.885 | 627.076 | 641.611 | 610.897 |
Prepaid Expenses | 4.779 | 6.753 | 10.937 | 11.067 | 3.952 |
Other Current Assets, Total | 2.73 | 1.367 | 1.259 | 1.042 | 8.646 |
Total Assets | 707.739 | 771.13 | 920.541 | 947.839 | 882.512 |
Property/Plant/Equipment, Total - Net | 28.89 | 27.15 | 25.588 | 22.916 | 21.805 |
Property/Plant/Equipment, Total - Gross | 46.067 | 45.287 | 42.035 | 37.344 | 38.402 |
Accumulated Depreciation, Total | -19.805 | -20.443 | -18.953 | -17.682 | -19.846 |
Goodwill, Net | 135.43 | 137.02 | 141.52 | 163.268 | 113.36 |
Intangibles, Net | 57.256 | 60.171 | 63.086 | 44.723 | 46.743 |
Other Long Term Assets, Total | 18.605 | 19.209 | 18.955 | 18.201 | 19.834 |
Total Current Liabilities | 183.578 | 216.027 | 264.908 | 271.64 | 276.79 |
Payable/Accrued | 114.797 | 139.555 | 176.881 | 185.507 | 192.032 |
Accrued Expenses | 60.202 | 59.313 | 73.268 | 76.737 | 75.436 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 8.579 | 17.159 | 14.759 | 9.396 | 9.322 |
Total Liabilities | 238.078 | 300.782 | 468.611 | 490.62 | 459.803 |
Total Long Term Debt | 0 | 31 | 138.443 | 148.735 | 129.755 |
Long Term Debt | 0 | 31 | 138.443 | 148.735 | 129.755 |
Deferred Income Tax | 0.247 | 0.237 | |||
Minority Interest | |||||
Other Liabilities, Total | 54.5 | 53.755 | 65.26 | 69.998 | 53.021 |
Total Equity | 469.661 | 470.348 | 451.93 | 457.219 | 422.709 |
Common Stock | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
Additional Paid-In Capital | 241.732 | 255.216 | 258.144 | 292.876 | 297.143 |
Retained Earnings (Accumulated Deficit) | 229.319 | 216.507 | 195.162 | 165.726 | 126.935 |
Other Equity, Total | -1.394 | -1.379 | -1.38 | -1.387 | -1.373 |
Total Liabilities & Shareholders’ Equity | 707.739 | 771.13 | 920.541 | 947.839 | 882.512 |
Total Common Shares Outstanding | 34.689 | 35.305 | 35.454 | 36.3026 | 36.508 |
Current Port. of LT Debt/Capital Leases | 0 | 0 | |||
Note Receivable - Long Term | 22.329 | 21.946 | 22.78 | 23.058 | 20.753 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 188.461 | 132.002 | -12.142 | -55.943 | -15.717 |
Cash From Operating Activities | 134.05 | -85.618 | 27.204 | 5.542 | 20.997 |
Cash From Operating Activities | 12.576 | 9.852 | 12.671 | 14.075 | 11.78 |
Deferred Taxes | 5.062 | -9.927 | -0.932 | 31.159 | -3.41 |
Non-Cash Items | 34.095 | 19.715 | 30.457 | 30.425 | 35.73 |
Cash Taxes Paid | 82.893 | 3.608 | 0.612 | 0.555 | 1.043 |
Cash Interest Paid | 12.859 | 5.773 | 2.666 | 4.554 | 6.34 |
Changes in Working Capital | -106.144 | -237.26 | -2.85 | -14.174 | -7.386 |
Cash From Investing Activities | -43.874 | -34.046 | -4.615 | -2.94 | -6.678 |
Capital Expenditures | -8.786 | -7.17 | -4.615 | -2.94 | -4.597 |
Other Investing Cash Flow Items, Total | -35.088 | -26.876 | 0 | 0 | -2.081 |
Cash From Financing Activities | -87.599 | 119.094 | -22.01 | -17.599 | -23.767 |
Financing Cash Flow Items | -17.05 | -8.583 | -2.018 | -4.697 | -2.643 |
Issuance (Retirement) of Debt, Net | -35.264 | 127.677 | -19.992 | -12.902 | -16.124 |
Foreign Exchange Effects | -0.009 | 0.006 | -0.011 | 0.01 | -0.07 |
Net Change in Cash | 2.568 | -0.564 | 0.568 | -14.987 | -9.518 |
Issuance (Retirement) of Stock, Net | -35.285 | 0 | 0 | -5 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 29.436 | 188.461 | 149.67 | 114.877 | 61.983 |
Cash From Operating Activities | 46.865 | 134.05 | 129.73 | -10.897 | -29.038 |
Cash From Operating Activities | 4.904 | 12.576 | 9.414 | 6.2 | 2.719 |
Non-Cash Items | 8.514 | 34.095 | 24.232 | 15.285 | 7.534 |
Changes in Working Capital | 4.608 | -106.144 | -56.383 | -150.735 | -103.702 |
Cash From Investing Activities | -3.496 | -43.874 | -6.763 | -3.848 | -2.096 |
Capital Expenditures | -3.678 | -8.786 | -6.763 | -3.848 | -2.096 |
Cash From Financing Activities | -46.681 | -87.599 | -93.674 | 13.987 | 31.308 |
Financing Cash Flow Items | -4.521 | -17.05 | -16.462 | -8.949 | -8.131 |
Issuance (Retirement) of Debt, Net | -10.4 | -35.264 | -52.864 | 22.936 | 39.439 |
Foreign Exchange Effects | -0.001 | -0.009 | -0.009 | 0.001 | -0.002 |
Net Change in Cash | -3.313 | 2.568 | 29.284 | -0.757 | 0.172 |
Deferred Taxes | -0.597 | 5.062 | 2.797 | 3.476 | 2.428 |
Other Investing Cash Flow Items, Total | 0.182 | -35.088 | 0 | 0 | |
Issuance (Retirement) of Stock, Net | -31.76 | -35.285 | -24.348 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cross Country Company profile
About Cross Country Healthcare, Inc.
Cross Country Healthcare, Inc. is engaged in providing total talent management services, including workforce solutions, contingent staffing, permanent placement, and consultative services. The Company operates through two segments: Nurse and Allied Staffing and Physician Staffing. The Nurse and Allied Staffing segment provides traditional staffing, recruiting, including temporary and permanent placement of travel and local nurse and allied professionals, managed services programs (MSP) services, education healthcare services, in-home care services, and outsourcing services. The Physician Staffing segment provides physicians in various specialties, certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments throughout the United States at various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cross Country Healthcare, Inc. revenues increased 100% to $1.68B. Net income totaled $132M vs. loss of $13M. Revenues reflect Nurse and allied staffing segment increase from $757.9M to $1.61B, Physician Staffing segment increase of 4% to $70.9M. Net Income reflects Nurse and allied staffing segment income increase from $75.3M to $205.7M, Unallocated Corporate Overhead segment loss decrease of 19% to $70.8M.
Equity composition
Common Stock $.0001 Par, 3/11, 100M auth., 31,102,682 issd., Insiders control 3.19%. Initial Public Offering 10/25/01, 7,812,500 shares @ $Ca17 by Merrill Lync & Co. *FY'99 = 5 months due to 7/30/99 inception of operations. *NOTE: 5/03, Name changed from Cross Country, FY'01 financials and Q's are restated for discontinued ops.
Industry: | Employment Services (NEC) |
6551 Park of Commerce Blvd.
BOCA RATON
FLORIDA 33487
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com